FUNDFACTS



GLOBAL INVESTMENT FUND (UK) ICVC

OGM OASIS CRESCENT GLOBAL EQUITY FUND

■ QUARTER 1 2021

Fund Manager	Adam Ebrahim	Min. Initial Investment	USD 5000
Launch Date	11 December 2020	Min. Additional Investment	USD 1000
Risk Profile	Medium to High	Fund Size	USD 267.2 million
Benchmark	MSCI ACWI Islamic USD Net Total Return Index (MSCI ACWI)	Total Expense Ratio	2.28%

The OGM Oasis Crescent Global Equity Fund (OGM OCGEF) is a Shari'ah compliant equity fund that seeks to provide an ethical investment product. The Fund conforms to moral and cultural beliefs.

Cumulative Returns

Cumulative	Dec 20	ec 2001	2001 2	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2014 2015	2016	2017	2018	2019	2020	YTD Mar	Return Since Inception	
Returns	2000	2001	2002	2005	2004	2005	2000	2007	2000	2007	2010	2011	2012	2013	2014	2013	2010	2017	2010	2017	2020	2021	Cum	Ann	
OGM Oasis Crescent Global Equity Fund	(0.0)	(2.0)	(0.7)	33.4	21.7	11.5	29.2	8.2	(37.6)	32.6	6.2	(4.7)	10.7	26.0	6.0	(3.3)	4.2	10.9	(10.9)	19.8	6.5	6.7	313.5	7.2	
Benchmark	(1.4)	(20.0)	(21.8)	25.2	8.4	6.6	16.4	14.9	(37.7)	25.3	7.5	(8.4)	8.0	11.8	1.8	(4.6)	5.7	21.9	(11.2)	22.7	11.9	5.2	77.9	2.9	

The Fund was launched following Oasis Crescent Global Equity Fund's ("OCGEF") merger with the Fund on 11 December 2020. The performance of OCGEF was assessed against the Average Shari'ah Global Equity Peer Group (the "Original Benchmark"). Performance is therefore shown against the Original Benchmark since inception until 11 December 2020 and against the new benchmark, the MSCI ACWI Islamic USD Net Total Return Index, subsequently.

Returns in USD Net-of-Fees Gross of Non Permissible Income (NPI) of the OGM OCGEF since inception to 31 March 2021. NPI for the 12 months to March 2021 was 0.02%. (Source: Oasis Research; Morningstar Direct; Bloomberg: December 2000 –March 2021)


Annualised Returns

Annualised Returns	% Growth 1 year	% Growth 3 year	% Growth 5 year	% Growth 7 year	% Growth 10 year	Return Since Inception Annualised	
OGM Oasis Crescent Global Equity Fund	38.1	7.5	6.4	4.9	6.3	7.2	
Benchmark	46.2	9.1	10.3	7.0	5.5	2.9	

Performance (% returns) in US Dollars, Net of Fees, Gross of Non Permissible Income of the OGM OCGEF since inception to 31 March 2021

(Source: Oasis Research; Morningstar Direct; Bloomberg: December 2000 - March 2021)

Investment Performance



(Source: Oasis Research; Morningstar Direct; Bloomberg: December 2000 - March 2021)

Risk Analysis

Oasis Fund vs. Benchmark	Sharpe	Sortino
OGM Oasis Crescent Global Equity Fund	0.34	0.47
Benchmark	0.05	0.06

Calculated net of fees Since Inception to 31 March 2021

(Source: Oasis Research; Morningstar Direct; I-Net Bridge; Bloomberg: December 2000 - March 2021)

Geographical Analysis

	March 2021						
REGION	OGM OCGEF %	MSCI ACWI %					
USA	62	37					
ROW	16	27					
EUROPE	10	25					
UK	9	4					
JAPAN	3	7					
Total	100	100					

Geographical split of the OGM OCGEF &

MSCI ACWI (31 March 2021)

Sectoral Analysis

SECTOR	OGM OCGEF %	MSCI ACWI %
Information Technology	26	22
Communication Services	24	1
Health Care	22	17
Consumer Discretionary	9	11
Materials	9	13
Energy	5	12
Consumer Staples	4	10
Real Estate	1	2
Financials	0	1
Industrials	0	8
Utilities	0	3
Total	100	100

Source: Oasis Research; Bloomberg: March 2021

Sectoral split of the OGM OCGEF & MSCI ACWI (31 March 2021)

Fund Manager Comments

The global economic contraction in 2020 was the worst in 50 years driven by the COVID-19 related lockdowns. The 3.3% decline in the global economy was better than expected due to massive synchronised monetary and fiscal stimulus. 2021 is expected to deliver the strongest global growth in many decades, with the global economy forecast to grow by 6.0%. 2022 growth is forecast at 4.4%. Continued monetary and fiscal stimulus supported by an aggressive vaccine rollout in some countries will boost the economic recovery. Global growth will be led by those countries like China and the U.S. (the 1st and 2nd largest world economies, respectively), which have aggressive vaccine rollouts and South-East Asia with a lower incidence of COVID-19. Regions like Europe, Latin America and Africa, who are lagging with the vaccine rollout, will have less robust economic recoveries. Factors that could boost global growth further are: a) the massive build-up in consumer savings; b) the wealth effect of robust financial markets; and c) pent-up demand. Factors that could constrain global growth are: a) new variants of COVID-19 b) sustainably high inflation c) a reversal of monetary and fiscal support d) constrained global supply chains, especially in logistics and semiconductors and e) continued geopolitical tension between US and China. In conclusion, the global economy should have robust growth in 2021 and the risks mainly impact 2022 onwards.

Global stock markets rebounded from their Covid 19 lows, with the OCGEF benchmark returning 46.2%, 5.2% and 2.9% for the year and quarter to end March 2021 and since the funds inception respectively. This performance was despite the weak economy. Global Equity markets benefited from a flood in liquidity provided by central banks, fiscal support to the economy and those sectors that benefited from the stay at home economy. The fiscal and monetary support will continue to support equity markets in 2021. The key risks include rising inflation, high valuations and a reversal in fiscal and monetary support. Over the last 100 years, equity markets (Dow Jones) delivered an annualised performance of 6.7% p.a. based on nominal GDP growth of 6.6% (3.1% p.a. real GDP growth and 3.5% inflation) and 0.1% of additional return for a total real return of 3.2% p.a. Based on this very long term history, as nominal GDP moves to 4.5% (2.5% real GDP and 2% inflation) with the 0.1% additional return, equity markets could return 4.6% p.a. nominal and 2.6% p.a. real.

Our fund, OCGEF has returned 38.1%, 6.7%, and 7.2% p.a. respectively over the last year, quarter to end of March and since inception. The OCGEF portfolio is focused on companies with market leadership, strong competitive advantages, sustainability, outstanding management, delivering high levels of profitability and cash flow and priced below intrinsic value. This together with a portfolio beta of 0.8%, positions the fund to deliver on its mandate.

Oasis Research, Bloomberg statistics, IMF World Economic Outlook

GIPS compliant & verified

Contact us:

The Oasis Global Management Company (Ireland) Ltd. Authorised by the Central Bank of Ireland and approved by the Financial Conduct Authority as the Authorised Corporate Director of the Fund.

Contact details:

Registration Number: 362471, 4th Floor, One Grand Parade, Dublin 6, Ireland,

Tel: +353 1 495 9800, Fax: +353 1 495 9888,

UK Free Phone: 0808 238 7543, Email: info@oasiscrescent.com,

www.oasiscrescent.com

C/O: 3rd Floor, 50 Hans Crescent, Knightsbridge,

London SW1X ONA, United Kingdom,

Tel: +44 (0) 2075900550 / Fax:+44 (0) 2075900555.

Email: info@oasiscrescent.co.uk www.oasiscrescent.co.uk

Disclaimer:

Undertakings for Collective Investments in Transferable Securities (UCITS) are generally medium to long term investments. Past performance is not

Warning: The value of your investment may go down as well as up and past performance is not a reliable guide to future performance.

Deductions for charges and expenses are not made uniformly throughout the life of the product, but are loaded disproportionately onto the early

A schedule of fees and charges is available from Oasis Global Management Company (Ireland) Ltd. ("the Authorised Corporate Director" or "ACD") on request. Portfolios are valued at 08h00 daily using the previous day's prices as at 22h00 GMT. All necessary documentation must be received before 14h00. Investments are made globally across a number of countries and currencies

Warning: This product may be affected by changes in currency exchange rates.

Prices are calculated on a net asset value basis which is the total value of all assets in the OGM Oasis Crescent Global Equity Fund, a "Sub-Fund" of OGM Oasis Crescent Global Investment Funds (UK) ICVC (the "Fund"), Registration Number: IC030383, including any income accruals and less any permissible deductions from the Sub-Fund which may include but not be limited to auditors fees, bank charges, custodian fees, management fees and investment advisory fees. UCITS can engage in borrowing and scrip lending and may borrow up to 10% of the market value of the portfolio to bridge insufficient liquidity

Warning: The income that an investor may get from an investment may go down as well as up.

The ACD is regulated by the Central Bank of Ireland. The Fund and the Sub-Fund are regulated by the Financial Conduct Authority and is managed by the ACD in accordance with the UK UCITS Regulations. Performance figures quoted are from Oasis Research and Bloomberg for the period ending 31 March 2021 for lump sum investment, using NAV-NAV prices with income distributions reinvested. Returns may vary depending on the actual date of investment and the actual date of reinvestment of income. The Key Investor Information Documents or a full Prospectus are available on request from the ACD and Oasis Crescent Management Company Ltd. The Sub-Fund is registered with the Financial Sector Conduct Authority for distribution in South Africa, the Swiss Financial Markets Supervisory Authority for distribution in Switzerland, the Monetary Authority of Singapore for distribution in Singapore and the Securities and Commodities Authority of the United Arab Emirates for distribution in the UAE. The Sub-Fund has a Total Expense Ratio (TER) of 2.28%, which is the average Net Asset Value of the portfolio incurred as charges, levies and fees related to the management of the portfolio, A higher TER does not necessarily imply a poor return, nor does a low TER imply a good return. The ratio does not include transaction costs. The current TER cannot be regarded as an indication of future TERs. Full details and basis of accolades received are available from the ACD and Oasis Crescent Management Company Ltd. All information and opinions provided are of a general nature and the document contains no express or implied recommendation, warranty, guidance, advice or proposal that the Sub-Fund is appropriate to the investment objectives, financial situation or needs of any individual or entity. All data and information (unless otherwise stated) is as at 31 March 2021.